Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy

Immunology

Volumn 136, Issue 4, 2012, Pages 437-447

  Gough, Michael J ^a   Killeen, N ^b   Weinberg, Andrew D ^a  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Arginase; Interleukin 12; Interleukin 18; Macrophage; OX40

Indexed keywords

ALPHA OX40 ANTIBODY; ARGINASE; CCL1 CHEMOKINE; CD11B ANTIGEN; CD134 ANTIGEN; CD14 ANTIGEN; CD4 ANTIGEN; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; CXCL16 CHEMOKINE; CXCL9 CHEMOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EOTAXIN 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOPROTEIN P 15095; IMMUNOMODULATING AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; NEURONAL NITRIC OXIDE SYNTHASE; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ARGINASE; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-18; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; RECEPTORS, OX40; TUMOR MICROENVIRONMENT;

EID: 84863205440     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03600.x     Document Type: Article

References (51)

1. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605-12.
2. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006; 25:315-22.
3. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117:1155-66 PMCID: 1857267.
4. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86:1159-66.
5. Linehan WM, Walther MM, Alexander RB, Rosenberg S. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute. Semin Urol 1993; 11:41-3.
6. Gough M, Crittenden M, Thanarajasingam U et al. Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J Immunol 2005; 174:5766-73.
7. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 2006; 66:1123-31.
8. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
9. Filippi CM, von Herrath MG. IL-10 and the resolution of infections. J Pathol 2008; 214:224-30.
10. Benoit M, Desnues B, Mege JL. Macrophage polarization in bacterial infections. J Immunol 2008; 181:3733-9.
11. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-91.
12. + memory T cell survival and significantly increases recall responses. Eur J Immunol 2007; 37:157-66.
13. Redmond WL, Gough MJ, Charbonneau B, Ratliff TL, Weinberg AD. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol 2007; 179:7244-53.
14. + T cell mobilization/memory development and humoral immunity: comparison of αOX-40 with αCTLA-4. J Immunol 2001; 167:6804-11.
15. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998; 161:6510-7.
16. Song A, Tang X, Harms KM, Croft M. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J Immunol 2005; 175:3534-41.
17. Matsumura Y, Hori T, Nishigori C et al. Expression of CD134 and CD134 ligand in lesional and nonlesional psoriatic skin. Arch Dermatol Res 2003; 294:563-6.
18. Yoshioka T, Nakajima A, Akiba H et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000; 30:2815-23.
19. Weinberg AD, Wegmann KW, Funatake C, Whitham RH. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 1999; 162:1818-26.
20. Weinberg AD, Rivera MM, Prell R et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000; 164:2160-9.
21. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 2008; 68:5206-15.
22. + regulatory T cells. J Exp Med 2005; 202:885-91 PMCID: 2213162.
23. Yang YF, Zou JP, Mu J et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res 1997; 57:4036-41.
24. Klinger M, Kim JK, Chmura SA, Barczak A, Erle DJ, Killeen N. Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands. J Immunol 2009; 182:4581-9.
25. Kim JK, Klinger M, Benjamin J et al. Impact of the TCR signal on regulatory T cell homeostasis, function, and trafficking. PLoS ONE 2009; 4:e6580 PMCID: 2719063.
26. Corraliza IM, Campo ML, Soler G, Modolell M. Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994; 174:231-5.
27. Gabrilovich DI, Bronte V, Chen SH et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67:425 author reply 6. PMCID: 1941787.
28. Baumann R, Yousefi S, Simon D, Russmann S, Mueller C, Simon HU. Functional expression of CD134 by neutrophils. Eur J Immunol 2004; 34:2268-75.
29. Pardee AD, McCurry D, Alber S, Hu P, Epstein AL, Storkus WJ. A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment. Cancer Res 2010; 70:9041-52.
30. Takeda I, Ine S, Killeen N et al. Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 2004; 172:3580-9.
31. Serhan CN, Brain SD, Buckley CD et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21:325-32.
32. Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6:1191-7.
33. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discovery 2004; 3:401-16.
34. Lawrence T, Willoughby DA, Gilroy DW. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002; 2:787-95.
35. Nair MG, Cochrane DW, Allen JE. Macrophages in chronic type 2 inflammation have a novel phenotype characterized by the abundant expression of Ym1 and Fizz1 that can be partly replicated in vitro. Immunol Lett 2003; 85:173-80.
36. Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 2003; 170:5064-74.
37. Rodriguez PC, Quiceno DG, Zabaleta J et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 2004; 64:5839-49.
38. Rodriguez PC, Zea AH, DeSalvo J et al. l-Arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol 2003; 171:1232-9.
39. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25:677-86.
40. Kuriyama H, Watanabe S, Kjaergaard et al. Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination. Cell Immunol 2006; 243:30-40.
41. Maxwell JR, Yadav R, Rossi RJ et al. IL-18 bridges innate and adaptive immunity through IFN-γ and the CD134 pathway. J Immunol 2006; 177:234-45.
42. Carson WE, Dierksheide JE, Jabbour S et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-γ production and STAT-mediated signal transduction. Blood 2000; 96:1465-73.
43. Darwich L, Coma G, Pena R et al. Secretion of interferon-γ by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18. Immunology 2009; 126:386-93 PMCID: 2669819.
44. Bursuker I, North RJ. Generation and decay of the immune response to a progressive fibrosarcoma II. Failure to demonstrate postexcision immunity after the onset of T cell-mediated suppression of immunity. J Exp Med 1984; 159:1312-21.
45. + effector T cells. J Exp Med 1984; 159:1295-311.
46. Zhang B, Karrison T, Rowley DA, Schreiber H. IFN-γ- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest 2008; 118:1398-404.
47. Cleveland RP, Meltzer MS, Zbar B. Tumor cytotoxicity in vitro by macrophages from mice infected with Mycobacterium bovis strain BCG. J Natl Cancer Inst 1974; 52:1887-95.
48. Vicetti Miguel RD, Cherpes TL, Watson LJ, McKenna KC. CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination. J Immunol 2010; 185:6706-18.
49. Munder M, Mallo M, Eichmann K, Modolell M. Murine macrophages secrete interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J Exp Med 1998; 187:2103-8.
50. Ruby CE, Montler R, Zheng R, Shu S, Weinberg AD. IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol 2008; 180:2140-8.
51. - T cell subsets to express IL-18 receptor and produce IFN-γ in response to IL-18. J Immunol 1998; 160:3759-65.